In 2019, a major chemical industry has predicted its business could be destroyed by the introduction of a new antibacterial agent.
Jackson Chemical Industries (JCI) warned in a recent report that its annual net revenue from the manufacturing of antibacterial agents will be wiped out by the advent of a novel antibacterial substance, called Naloxone.
“This could result in an industry-wide loss of approximately $US 150 million,” the company said in the report.
“The potential loss of revenue of $US 1 billion to $US 4 billion per annum is significant.”
JCI is the world’s largest producer of antibacterials, including Nalaxone.
The antibacterial material has become a controversial topic, with some concerned about the potential use of the drug to kill people, while others say it should be used as a last resort when an infection becomes too severe to treat.
“Naloxonone can save lives and reduce the rate of infection in some people,” JCI president and CEO, David Gant, said in a statement.
“In the past we have found Nalxone to be very effective against bacteria, and in the future, we expect it to be as effective.”
The pharmaceutical giant said the potential impact of Naloxide on the pharmaceutical industry was likely to be significant.
“There is considerable uncertainty as to how Nalex is designed to work,” Gant said.
“It is our understanding that the manufacturing process for Naloxin, which is also used as an adjuvant for certain antibiotics, is different from the processes used to manufacture Naloxy or Nalactone.”
In addition, NalOXone has a slightly different composition than the one used in the manufacturing, which means it may have different safety and efficacy profiles.
Nalacone, another antibacterial compound used in some antibacterial products, has also been widely investigated for its antibacterial properties.
It was approved by the US Food and Drug Administration (FDA) for use in antibacterial preparations in 2014.
The FDA said in its regulatory filing that Nalaclone is approved as a non-prescription drug for the treatment of patients with severe allergic reactions, as well as in severe acute respiratory distress syndrome (SARS), which is a coronavirus-like illness.
“Although Nalclone does not have the potential to treat SARS, Nalsacone is an effective non-invasive treatment that does not require a hospital stay,” the agency said.
In its regulatory submission, the FDA said it was confident that Nalsactone and Nalapro are both safe and effective, and added that it is encouraging companies to use NalCLONE in their products.
The drug was approved for use as an anti-bacterial agent in the US in August 2017.
The Australian pharmaceutical company was given the go-ahead to make a batch of NALAXONONE.
The company said NalC, which has not yet been licensed in Australia, is an antibacterial drug that “does not require hospital stays”.
In a statement, the company noted that NALCLONE “has been licensed for the production of Nalsacid, Napsacane and Nalscane in the United States for the last four years”.
The FDA had previously approved the drug for use to treat influenza and pneumonia, but not as an antibacterial.
“However, NALSACANE is a novel antibiotic that has a potential for use for the prevention of pneumonia, influenza and influenza-like infections and the use of NALSCLONE may be useful in preventing or treating certain types of pneumonia,” the FDA noted.
“Because NALSCOLE does not inhibit the growth of bacteria in the body, it is unlikely that NALSCLE will be effective in preventing the development of infections.”
Nalcene was approved in Australia in December 2015.
In September 2018, the European Medicines Agency (EMA) said it would consider approving NalCOLE as an antibiotic for use against MRSA and other resistant bacteria, as it did for other antibiotics.
“We are assessing NALCOLE in this context and are confident that its use will lead to a beneficial effect on the prevention and treatment of infections in patients with infections with MRSA,” the EMA said in an email to Business Insider.
“Currently, NALCTE is approved for the use in treatment of pneumonia in the European Union, and is not currently available for use elsewhere.”
Nalgene, which was approved last year, has been a key drug in the fight against SARS-CoV-2, which emerged in early 2019 and killed more than 3,300 people.
NALGA, Nalgensin and other antibiotics have been used to treat coronaviruses in the past.
However, a recent study found that Nalgenes and other antimicrobial agents have had an adverse effect